@article{Drew Provan_Tom Butler_Maria Laura Evangelista_Sergio Amadori_Adrian C. Newland_Roberto Stasi_2007, place={Pavia, Italy}, title={Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults}, volume={92}, url={https://haematologica.org/article/view/4672}, DOI={10.3324/haematol.11709}, abstractNote={We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7 patients with idiopathic thrombocytopenic purpura and in 1 patient with autoimmune pancytopenia. A partial response was observed in 1 patient with autoimmune hemolytic anemia. The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients.}, number={12}, journal={Haematologica}, author={Drew Provan and Tom Butler and Maria Laura Evangelista and Sergio Amadori and Adrian C. Newland and Roberto Stasi}, year={2007}, month={Nov.}, pages={1695-1698} }